Medicinal Chemist.
AI Architect.
Decision Intelligence Engineer.

Transforms any AI into the world's most effective aptitude and logical reasoning educator. Built on 10 non-negotiable teaching laws, a complete error-diagnosis system, and mastery of every LR type tested in NIPER JEE and GPAT. Takes any student from complete beginner to exam-ready through structured, shortcut-first, analogy-driven teaching.

Makes any AI a dedicated quantitative aptitude wizard — purpose-built for the deep mathematics sections of NIPER JEE, GPAT, CAT, and banking exams. Teaches every formula through its logical story first, then delivers the fastest shortcuts available. No formula is taught without the "why" that makes it unforgettable.

Your dedicated verbal reasoning coach — engineered for CAT VARC, GMAT Verbal, GRE, Banking English, and the verbal sections of NIPER JEE. Teaches RC through logical reading structure, CR through argument mapping, grammar through root principles, and vocabulary through Latin and Greek roots that permanently unlock 2,000+ words.

Built exclusively for pharmacy students — teaches General Knowledge, Intellectual Property Rights, and Pharma Management entirely through real pharmaceutical examples. TRIPS, Section 3(d), compulsory licensing, CDSCO, NPPA, DPCO, patent cliffs, and every pharma MBA concept taught through real drug stories that make abstract law and business permanently memorable.

Transforms any AI into a McKinsey-veteran case interview coach with 15+ years of top consulting experience. Covers every major case type — profitability, market entry, growth, cost reduction, valuation, strategy, M&A, organisational restructuring — with MECE frameworks, mental math techniques, real case simulations with curveballs, and the exact communication style that lands offers at McKinsey, BCG, Bain, and top pharma companies. Built on 5 non-negotiable operating principles and 6 essential frameworks, this prompt also covers interview psychology, pacing, and real consulting project reality — what actually happens after the offer.

Makes any AI a world-class estimation coach — 20+ years of Fermi estimation expertise combined with market sizing mastery and business intuition building. Covers the 5-step Fermi method, top-down and bottom-up decomposition, key driver sensitivity analysis, 7 critical mistakes to avoid, a calibration table of 20+ business metrics (SaaS, pharma, FMCG, consulting, retail), and pharma-specific estimation problems unique to NIPER placements. Teaches the exact thinking-out-loud technique that impresses interviewers at McKinsey, BCG, data science, and pharma MBA interviews.

The complete placement intelligence suite — senior recruiter + interview strategist + career coach in one. From building an ATS-beating resume to salary negotiation to first-90-days excellence. Covers 5 operating principles: Resume Mastery, STAR Behavioral Framework, Salary Negotiation, Career Compound Growth, and Interview Psychology. Makes any AI into a world-class placement expert that knows exactly what hiring managers score — and what kills candidacy silently.

Transforms any AI into an elite HR interview coach — recruiting director + HR psychologist + communication coach in one. Teaches the exact 5 dimensions HR actually scores (Communication 25%, Attitude 25%, Career Clarity 20%, Truthfulness 20%, Presence 10%), STAR storytelling, self-introduction mastery, company research strategy, and frameworks for the hardest HR questions. Builds authentic confidence, not rehearsed scripts. 95% first-round pass rate methodology.

Converts any AI into a seasoned pharma technical interviewer — former R&D director + QA/RA expert + formulation scientist in one. Drills candidates on every technical domain: pharmaceutical sciences, analytical chemistry, formulation development, regulatory science, pharmacokinetics, and drug discovery. Simulates real technical interviews at Sun Pharma, Dr. Reddy's, Lupin, Cipla, Aurobindo, and global MNCs with authentic question depth and expert-level feedback.

Purpose-built for pharma/biotech placements, research institute interviews (CSIR/DBT/ICMR), and PhD admissions. Covers molecular biology, biochemistry, immunology, cell biology, genomics, and experimental design — from conceptual foundations to disease case studies. Uses analogy-first teaching and structured experimental frameworks. Prepares candidates for everything from campus placements to competitive research interviews at Biocon, Serum Institute, and top-5 global biotechs.

The most rigorous QA interview simulation available — built by an 18-year veteran who has managed 400+ audits, 12 US FDA PAIs, 8 MHRA inspections, and guided 3 Warning Letter remediation programmes to full FDA clearance. Drops you straight into real quality events — OOS investigations, CAPA design, data integrity crises, and unannounced FDA inspection scenarios. Zero tolerance for "retrain the operator" as a root cause. ALCOA+, Phase 1/Phase 2 OOS, Form 483 response — all tested to expert standard.

25-year veteran educator and interviewer who has trained 40,000+ RA/QA professionals and reviewed 600+ CTD dossiers, 120+ ANDA submissions, and 40+ NDA/MAA filings. Operates in two modes: Master Educator (teaches every concept with story-first, guideline-number-second methodology) and Expert Interviewer (simulates real pharma RA interviews from fresher to Senior Director level). Covers FDA, EMA, CDSCO, ICH Q8/Q9/Q10, CTD format, pharmacovigilance, ANDA/NDA strategy, and inspection readiness.

15-year field veteran — MR to Regional Sales Manager — who has trained 3,000+ Medical Representatives at Cipla, Abbott, and Torrent Pharma with a 78% first-year target achievement rate (industry average: 51%). Simulates real doctor cabin scenarios with authentic pressure, interruptions, and objections. Teaches the 30-second pitch law, patient-first language, the acknowledge-pivot-ask objection framework, and territory strategy. Turns pharmacy graduates who freeze in a cabin into confident, patient-focused field professionals.

14-year methodological specialist in Real-World Evidence — designed 23 RWE studies for FDA submissions, published in NEJM Evidence, and built the target trial emulation SOP adopted across a 40-analyst team. Drills candidates on the complete PICOTS framework, active comparator new user design, the 7-bias identification system (confounding by indication, immortal time bias, depletion of susceptibles, and 4 more), propensity score methodology, causal inference tools (IPTW, DiD, IV, RDD), and FDA RWE framework for regulatory submissions. Turns data analysts into causal evidence architects.

THE STRUCTURE FORGE — 15+ years in protein structure, AlphaFold analysis, molecular dynamics, and structure-based drug design. Zero tolerance for "I'll run AlphaFold" without a biological question. 10 laws cover AlphaFold confidence scoring, binding site identification, MD as hypothesis-testing, druggability assessment, allosteric targeting, and the chemistry translation mandate. 10 superpowers include full Python pipelines for virtual screening, cryptic pocket detection, mutation effect prediction, and GROMACS/AMBER MD workflows.

THE STRATEGY ANALYTICS FORGE — 14+ years at ZS Associates, McKinsey Health, BCG Pharma, IQVIA Consulting. Zero tolerance for frameworks before problem structure. 10 laws: hypothesis-driven structure, market sizing as logic chain, Porter's Five Forces applied (not academic), drug launch decision trees, 3-anchor pricing strategy, quantitative reasoning, 30-second CEO summary. Python code for NPV launch models, competitive positioning matrices, MECE issue trees, and scenario analysis — all production-grade.

THE SYNTHETIC ORGANIC CHEMISTRY FORGE — 16+ years in total synthesis, medicinal chemistry, and late-stage functionalization. Corey disconnection approach, complete cross-coupling arsenal (Suzuki/Negishi/Buchwald-Hartwig/C-H activation), stereocontrol masterclass, protecting group strategy, named reactions, LSF paradigm. Real synthesis challenges: imatinib retrosynthesis, stereochemical puzzles, troubleshooting failed reactions, commercial route optimization. Python retrosynthesis analyzer and protecting group compatibility checker included.

THE ML PHARMA FORGE — 13 years building ML across drug discovery, clinical analytics, EHR-RWE, and commercial pharma AI. 10 laws include: Problem Formulation first, 4-Layer ML Framework, Baseline before Complexity, Data Bias as Patient Safety, Temporal Validation mandatory, Interpretability as regulatory requirement, Feature Leakage as the most dangerous error, Deployment failure modes. Complete Python pipelines: patient response prediction, survival analysis, HCP uplift modeling, ADR signal detection, and clinical NLP with BioBERT/ClinicalBERT.

THE ANALYTICAL CRUCIBLE — 15 years, 300+ validated methods, Dr. Reddy's to Lupin, 4 FDA Pre-Approval Inspections with zero observations. Every chromatographic parameter must be mechanistically justified — not textbook-quoted. 10 laws cover the Parameter Justification Mandate, 4-Layer Analytical Framework, Forced Degradation before Finalization, LOD/LOQ ICH truth, Column Chemistry principles, Robustness by Design, and Impurity Identification as regulatory obligation. 10 case scenarios: peak tailing, co-elution, failed mass balance, residual solvent OOS, unknown impurities, method transfer failures.

THE GENOME FORGE — 15 years, 3,200+ RNA-seq samples processed, 11 peer-reviewed papers, FDA companion diagnostic pipeline validated. Zero tolerance for pipeline execution without biological question definition. 10 laws: biological question first, 4-layer bioinformatics framework, confounder detection mandatory, biological replicates non-negotiable, FDR not p-value, pathway enrichment as translation layer, TME as confounder AND signal, pseudoreplication is career-ending. Complete pipelines: 9-stage bulk RNA-seq, GATK Best Practices WES/WGS, Seurat scRNA-seq with pseudobulk, multi-omics MOFA, ChIP-seq/ATAC-seq, spatial transcriptomics.

THE CLINICAL ORACLE — 25 years, 40,000+ students, 3,200+ CRO placements (IQVIA, Syneos, PPD, ICON, Parexel) with 81% selection rate. Every clinical research concept taught through story first, regulation second — using 10 laws including Zero Assumption, Fear Neutralizer, Error Taxonomy, and Interview Strategy as half the offer. Covers GCP with Thalidomide origin story, Trial Phases 1-line framework, SAE/SUSAR/AE reporting chain, CRA monitoring visits, ICF as process not signature, and the 30-second pivot technique for freshers with no site experience.

THE CLINICAL DATA SCIENCE FORGE — 15 years across Novartis, Roche, Pfizer, FDA submissions, ICH E9(R1). Led Phase III oncology trial stats (KRAS G12C inhibitor, n=847, OS HR 0.71, FDA approved), built adaptive enrichment designs for immunotherapy trials (published Lancet Oncology), trained 151 clinical data scientists. 10 laws including Estimand-before-Analysis, 5-Layer CDS Framework, PH Assumption Gate, Multiplicity FWER control, Missing Data tipping point, and ML in trials validation rules. Full CDISC SDTM/ADaM coverage, survival analysis, biomarker stratification, and regulatory submission analytics.

THE SUBMISSION FORGE — 14 years, 6 NDA/BLA submissions (2 priority reviews), IQVIA/Covance/PPD. Built TEAE derivation macro library (94% error reduction across 22 programs), designed ADTTE from first principles for 1,200-patient Phase III oncology trials, reviewed 47 define.xml submissions (most common error: missing computational methods — triggers FDA Information Request in 30% of first submissions). 10 laws: Derivation Logic before Code, CDISC Compliance, TEAE Derivation Mandate, define.xml Completeness, QC Independence, and the critical gap between "code that runs" and "code that survives regulatory audit."

THE BIOSTATISTICS FORGE — 16 years, FDA/EMA/ICH E9(R1), designed SAP for Phase III CV outcomes trial (n=14,000, MACE composite, FDA approved, 7 international guidelines), Bayesian adaptive dose-finding SAPs (BLRM/EWOC, 40% faster MTD, 22% fewer patients at toxic dose), multiplicity strategy for 4-endpoint NDA (all 4 claims accepted without modification). 10 laws: Estimand before Method, Complete Method Selection tree, Hypothesis Testing precision, PH Assumption Gate, Multiplicity FWER control, Missing Data Tipping Point, Bayesian Go/No-Go, and 60-second FDA presentation. Transforms test-pickers into statistical evidence architects.

THE PHARMA BD CRUCIBLE — 20 years, 500+ deals evaluated, $4.2B+ cumulative deal value, Novartis/AstraZeneca/Sun Pharma. 10 laws including the 4-Layer Deal Framework (Asset + Market + Economics + Strategic Fit), No "It Depends" Without a Conclusion, rNPV in 5 Numbers, Competitive Map before Valuation, ZOPA negotiation architecture, and 6 classic pressure tactics decoded. 10 live deal cases: Phase II oncology, biosimilar race, NASH mid-trial exit, India geo-licensing, hostile competitive move, 90-day Head of BD challenge. Transforms science candidates into deal table voices who think like a CFO and CMO simultaneously.

THE CHEMINFORMATICS FORGE — 15 years, QSAR/ADMET pipelines, RDKit/DeepChem/Chemprop. Published benchmark comparison of ECFP4 vs MACCS vs Mordred vs GNN vs transformer across 12 ChEMBL datasets (251 citations — changed field default from ECFP4 to GNN for datasets >2,000). Reduced late-stage ADMET attrition by 41%; identified 3 novel kinase scaffolds via virtual screening. 10 laws: Chemical Question Gate, Representation Selection Benchmark, Applicability Domain Mandate, Activity Cliff Awareness, ADMET as patient safety, Scaffold-Split Validation, 4-Stage Virtual Screening Funnel, Generative Design reality check, ICH M7/OECD regulatory cheminformatics, and Medicinal Chemist Trust Protocol.

THE STRATEGY ANALYST FORGE — 18 years, ex-MBB Partner / Pharma Head of Strategy. Led $4B portfolio prioritization, executed 12 M&A integrations, and designed the "Sovereign Intelligence" framework for top-10 global pharma. 10 laws: Value before Volume, rNPV Sensitivity Mandate, Competitive Edge Forensics, Walk-Away Logic, and LOE Planning. Transforms analysts into strategic architects.

THE MARKETING ANALYTICS FORGE — 18 years, Chief Commercial Officer grade. Optimized $1B+ launch budgets, built next-best-action AI engines with 40% engagement lift, and designed global commercial frameworks for top-3 pharma. 10 laws: Forensic Attribution, Prescriber DNA, Omnichannel Orchestration, Dynamic MMM, and Patient Journey Forensics.

THE MOLECULAR BIOLOGY FORGE — 20 years, CRISPR/Cas9 pioneer, led target validation for 5 drugs now in clinic. Master of the central dogma and its high-throughput interrogations. 10 laws: Target validation is destiny, Off-target Forensics, Mechanism of Action Mandate, Multi-omics Integration, and the Reproducibility Protocol.

THE MEDICINAL CHEMIST FORGE — 25 years, ex-VP MedChem. Lead inventor on 5 approved drugs. Master of MPO, SAR forensics, and covalent kinetics. 10 laws: MPO is Sovereign, SAR Forensics, Metabolic Shielding, Bioisostere Bible, and Warhead Management.

THE PROCESS R&D FORGE — 18 years, scaled 10+ APIs from mg to Metric Ton. Master of green chemistry, safety, and regulatory-grade process validation. 10 laws: Safety first, Cost is king at scale, Regulatory starting materials, Solvent selection, and the Impurity Control Strategy.

THE MEDICAL WRITER FORGE — 18 years, authored 6 major NDAs/BLAs and 60+ peer-reviewed papers. Master of regulatory narrative architecture, CTD Module 2/5 strategy, and Benefit-Risk forensics.

THE AI-DRUG DISCOVERY FORGE — The singularity of AI and Pharma. 15 years at top AI-biotechs, built generative pipelines for 5+ clinic-ready assets. 10 laws: Data is the new oil (clean only), Model interpretability is safety, Generative design reality check, Digital Twins, and the Autonomous Lab.

THE ML PHARMA FORGE — 13+ years, built clinical ML systems for 3 Phase II oncology trials and FDA-cleared SaMD products. 10 laws: Problem formulation before model selection, Temporal leakage is the cardinal sin, Calibration alongside discrimination, Baseline before complexity, CMO communication standard. Zero tolerance for "I'll use Deep Learning" without justification.

THE ANALYTICS COMMAND CENTER — 14+ years, 600+ analytics projects for Abbott, GSK, Torrent, Alkem, and Dr. Reddy's. 10 laws: Business question primacy, 4-layer analytics framework, Hypothesis-first analysis, The Why Ladder (3 levels minimum), 30-second stakeholder rule. Zero dashboards without decisions.

THE INSIGHT ENGINE — 16+ years, 800+ research studies for Pfizer, Novartis, Roche, AZ, and Sanofi. Insights that influenced $2.4B in brand strategy decisions. 10 laws: The Insight Mandate (So What / Decision / Surprise), MECE backbone, Pyramid Principle non-negotiable, Competitive intelligence is forward-looking signals, not history. Zero presentations without impact.

THE MEDICAL CODING VAULT — 18+ years, 500,000+ claims audited, $42M in coding errors found across 12 audit engagements. Built compliance programs for a 1,200-bed academic medical center. 10 laws: Justification Mandate, Combination codes over multiple codes, Outpatient/Inpatient rules never interchangeable, Modifier is a certification not a decoration, Specificity is a compliance obligation.

THE PHARMA PM FORGE — 25+ years, 10,000+ candidates mentored for PMT roles at Novartis, Cipla, Sun Pharma, Abbott and Lupin. Commercial brands worth ₹200 Cr+ across cardiovascular, oncology and CNS. 10 laws: Business Outcome First, 3-Layer Answer Framework, Scenario Before Theory, Answer Diagnosis System, Stakeholder Reality Check. Zero clinical answers to commercial questions.

THE PHARMA ORACLE — 20+ years, 2,400+ final-round consulting interviews at IQVIA, ZS Associates and BCG Health. 340 candidates placed at McKinsey, BCG, Bain and IQVIA. 10 laws: D-H-T-R Interview Cycle, MECE minimum standard, Hypothesis-First always, Science-to-Business translation, Quantify or withdraw the claim. Zero hedging on final recommendations.

THE PHARMA CI ORACLE — 22+ years, 8,000+ professionals trained, CI functions built at 3 major pharma companies recognised by SCIP as best-in-class. Intelligence that shaped $500M+ pipeline and launch decisions. 10 laws: Decision-linked intelligence, KITs & KIQs planning, Living landscape model, Ethics as foundation, BLUF delivery always. Zero reports that change no decisions.

THE MARKET ACCESS & HEOR ORACLE — 25+ years, 10,000+ professionals trained, 8 NICE-approved submissions including 2 reversals. V-A-L-U-E Teaching Cycle across NICE, G-BA, HAS, PBAC and CADTH. 10 laws: QALY in plain English, HTA stakeholder map first, Budget Impact story, Managed Entry agreements, Global launch sequencing. Zero acronyms before understanding.

THE COMMERCIAL INTELLIGENCE FORGE — 14+ years, 240+ commercial analysts trained at IQVIA, ZS Associates, Axtria and Deloitte Life Sciences. Commercial recommendations that reallocated ₹40 crore field force budgets and identified launch failures 6 weeks early. 10 laws: Problem Structure Before Data, 5-Driver Commercial Diagnostic, Prescription Metric Hierarchy, Decile Segmentation to Action, So What Test mandatory. Zero TRx reports without a diagnostic hypothesis.

THE CHEMINFORMATICS FORGE — 15+ years, 220+ computational and medicinal chemists trained across pharma R&D and AI-native drug discovery. ADMET prediction suite with 94% coverage that reduced late-stage attrition by 41% over 4 years. 10 laws: Chemical Objective Before Representation, 5-Layer Framework, Data Curation is 60% of the problem, Scaffold Split always, Applicability Domain before trusting any prediction. Zero fingerprint choices without chemical justification.

THE SUBMISSION FORGE — 14+ years, 154 clinical SAS programmers trained across global CROs and top-10 pharma sponsors. Led 6 NDA/BLA submissions including 2 priority reviews with PINNACLE 21 score of zero critical errors. 10 laws: Derivation Logic Before Code, 4-Layer Clinical Programming Framework, Traceability as proof not documentation, TEAE edge cases all covered, Double Programming mandatory. Zero SAS code without a documented derivation algorithm.

THE PHARMA R&D REACTOR — 15+ years, 200+ formulations from preformulation to tech transfer. Sun Pharma SPARC, Dr. Reddy's, Lupin, Cipla. 14 NDA/ANDA filings, zero CRL on CMC. 10 operating laws: Justification Mandate, 4-Layer Formulation Framework, Troubleshooting Inversion, Scale-Up Reality Check, QbD non-negotiable.

THE ANALYTICAL CRUCIBLE — 15+ years, 300+ analytical methods developed and validated. Dr. Reddy's AR&D, Lupin, Wockhardt, Syngene. 18 method-related FDA submissions with zero analytical queries. 10 operating laws: Parameter Justification Mandate, 4-Layer Analytical Framework, Forced Degradation before finalization, Robustness is designed not discovered.

THE MARKETING INTELLIGENCE FORGE — 14+ years at IQVIA, ZS Associates, Axtria, Publicis Health. NPI-level attribution linking detailing and digital touchpoints to physician TRx behavior. 10 operating laws: Revenue Attribution Mandate, Campaign ROI Framework, CLM funnel diagnostics, Optichannel scoring, SFE measurement.

THE STRATEGY ANALYTICS FORGE — 14+ years at ZS Associates, McKinsey Health, BCG Pharma, IQVIA Consulting. Drug launch strategy, portfolio prioritization, market entry decisions, pricing. 10 operating laws: Problem Structure before Framework, MECE non-negotiable, Hypothesis-Driven, Market Sizing is logic not lookup.

THE MOLECULAR FORGE — 16+ years in structure-based drug design, MD simulations, QM/MM, FEP, QSAR, deep learning for molecular property prediction. 11 drug targets, 3 preclinical candidates. GNN models achieving 29-fold enrichment. 10 operating laws: Biological Question before Docking, Physics-First validation.

THE GENOME FORGE — 15+ years in RNA-seq, WGS, WES, ChIP-seq, ATAC-seq, scRNA-seq, spatial transcriptomics, multi-omics integration. 3,200+ RNA-seq samples. TMB/MSI companion diagnostic pipeline for FDA submission. 10 operating laws: Biological Question before Pipeline, QC is non-negotiable, Batch Effect is the silent assassin.

THE BIOSTATISTICS FORGE — 16+ years designing Phase I-IV trials, SAPs for FDA and EMA. Cardiovascular outcomes trial (n=14,000), Bayesian adaptive dose-finding, multiplicity for 4-endpoint NDA. 10 operating laws: Estimand before Endpoint, SAP before Database Lock, Multiplicity is integrity not bureaucracy.

THE MOLECULAR BIOLOGY FORGE — 15+ years in cancer biology, CRISPR, RNAi, qPCR, cloning, Western blot, flow cytometry, functional assays. CRISPR KO in KRAS-mutant PDAC published in Cancer Cell. Base editing screen for synthetic lethality. 10 operating laws: Biological Question before Protocol, Controls are the experiment.

THE STRUCTURE FORGE — 15+ years in protein structure prediction, binding site analysis, MD, SBDD, deep learning for structural biology. AlphaFold2 cryptic pocket identification leading to Phase I. 10,000+ MD trajectories. 10 operating laws: Structure is a hypothesis not a fact, AlphaFold is a prediction tool not an oracle.

THE PHARMACOVIGILANCE ORACLE — 25 years, ex-Global Head of PV. Coached 20,000+ candidates with 81% placement rate. Master of ICSR lifecycle, signal detection, and regulatory submissions. 10 laws: Human Story First, Seriousness/Expectedness/Causality Trinity, Timeline Precision, and Risk Management.

Transforms raw clinical trial data into a tiered economic value narrative for hospital P&T committees, national payers, and managed care organizations — with QALY modeling, budget impact framing, and cost-offset sequencing.

Evaluates how regulatory policy shifts (IRA, EMA HTA reform, EU pharmaceutical legislation) impact drug pricing power, R&D ROI, launch timing, and commercial trajectory — across three scenario branches.

For clinical operations managers facing delayed enrollment. Analyzes I/E criteria to identify optimal geographies, patient advocacy partnerships, digital recruitment channels, and de-risking tactics for behind-schedule trials.

Simulates geopolitical, API sourcing, and manufacturing disruption scenarios against a pharma supply network. Produces risk-ranked disruption trees, dual-sourcing strategies, and resilience protocols with operational timelines.

For brand managers preparing pre-launch or launch messaging. Takes clinical data and produces a differentiated messaging matrix across three stakeholder types — Payers, Physicians, and Patients — with proof points, objection handlers, and channel guidance.

Translates clinical definitions into production-grade SQL cohort queries for Optum/Truven/CPRD EHR and Claims databases. Generates inclusion/exclusion logic with ICD-10/NDC/CPT code placeholders, HEDIS-aligned washout periods, index date logic, and optimised query performance annotations.

Generates Python (Pandas/NumPy) and SQL scripts to automatically detect 8 classes of clinical trial data anomalies — missed visits, out-of-range vitals, duplicate IDs, protocol deviations, data entry errors, audit trail gaps, CDISC SDTM non-conformance, and statistical outliers — adhering to ICH E6(R3) GCP and CDISC standards.

Produces the full Python analytical framework for merging Veeva CRM (sales rep call data) with IQVIA IQVIA NPA/IQVIA DDD prescription volume data. Generates ROI attribution, territory performance ranking, script decay rate modelling, rep efficiency scoring, and digital vs F2F channel contribution analysis.

Guides data scientists through building a full patient non-adherence prediction pipeline: feature engineering from Claims data, refill gap analysis, SDoH integration, XGBoost vs. Cox Proportional Hazards vs. DeepSurv algorithm selection with rationale, SHAP explainability, and starter Python code with clinical validation framework.

Specialised debugging system for computational biology errors in NGS, scRNA-seq, and structural biology workflows. Diagnoses dependency conflicts, memory limits, statistical errors, and library-specific failures in Bioconductor (DESeq2, edgeR, limma), Seurat, Scanpy, GATK, and AlphaFold pipelines, with corrected code output.

Evaluates clinical evidence against ICER and multi-HTA payer standards, scores the value dossier readiness across 7 domains, generates a premium pricing justification architecture, and identifies the critical evidence gaps before HTA submission.

Transforms raw physician characteristics into 5 strategic adoption tiers, generates a behavioural profile for each segment, and outputs a fully tailored omnichannel engagement playbook with channel mix, message architecture, call frequency, and conversion KPIs for every tier.

Full KOL intelligence profile: publication authority mapping, trial network influence scoring, speaking engagement reach analysis, sphere-of-influence classification across peer/institutional/payer dimensions, and a tailored Medical Affairs engagement strategy with specific activity recommendations and relationship risk flags.

Strategic sales force restructuring framework: territory potential scoring, optimal rep deployment modelling across 3 scenarios, call frequency optimisation by HCP tier, digital vs face-to-face resource allocation with ROI rationale, and a competitive coverage gap analysis with redeployment recommendations.

Full omnichannel marketing ROI analysis: channel attribution modelling, cost-per-Rx by touchpoint, touchpoint sequence effectiveness, budget reallocation optimisation across 3 scenarios, diminishing returns detection, and a 90-day channel mix redesign roadmap to maximise script conversion.

Transforms rival launch intel into a full war-game: 3 probabilistic scenarios with share curves, Nash equilibrium pricing prediction, payer access modelling, and a 6-tactic prioritised defensive playbook with KPIs.

Full commercial audit of a draft TPP: 8-attribute SoC gap table with impact scoring, vulnerability register with addressability ratings, HTA evidence package audit, unmet needs gap map, and 5 evidence-anchored peak-sales pivot points with revenue tier estimates.

Full patent cliff defence architecture: 9-lever scorecard with Feasibility × Revenue Priority matrix, 3-year cliff erosion model, top-3 recommended levers with exclusivity months, Paragraph IV litigation signals, payer lock-in playbook, and a Q-by-Q 36-month milestone roadmap.

Pre-diligence biotech acquisition screen: executive go/no-go verdict, P1–P3 regulatory risk register, clinical red flag forensics with PoS impact, full pipeline synergy table with strategic fit scores, and risk-adjusted NPV signal with value creation and destruction scenarios.

End-to-end launch excellence orchestration: 6-pillar readiness scorecard (Medical/Commercial/Market Access/KOL/Supply/Digital), critical path milestone tracker, peak-year-1 revenue forecast with assumption model, and a launch risk register with mitigation triggers.

Strategic portfolio and pipeline prioritisation: rNPV-ranked asset matrix, resource allocation optimisation across the pipeline, capability gap identification, BD/licensing white-space map, and a 3-year portfolio strategy with kill/accelerate/partner decision logic for each asset.

Systematic literature search specialist: PICO decomposition, multi-database Boolean strategy construction (PubMed, Embase, Cochrane), PRISMA 2020 documentation, and grey literature protocol — publication-ready evidence retrieval.

Senior scientific manuscript architect: IMRaD structure engineering, journal-specific targeting (Nature, NEJM, JAMA), EQUATOR-compliant statistical reporting, and peer-review response strategy.

Strategic presentation architect: SCQA narrative framework, Ghost Deck methodology, Minto Pyramid Principle, action-title engineering, and data-visualization design for C-suite, FDA, and investor audiences.

Principal-level pharma strategy consultant: drug development strategy, MECE issue-tree decomposition, regulatory intelligence (FDA/EMA/ICH), competitive landscape, M&A due diligence, and commercial launch architecture.

Pharmaceutical operations and general management advisor: R&D ops, GxP quality systems, CMO/CDMO governance, medical affairs, AI transformation strategy, and enterprise KPI design — with ICH compliance integration.

Automated internal audit engine for corporate expense reports: 8-violation-class detection (duplicates, excessive amounts, unapproved vendors, split transactions, weekend/holiday claims, missing receipts, policy-ceiling breaches, unusual patterns), SOX/COSO-aligned Risk Scorecard generation, Python analytics pipeline, and Excel reviewer interface with prioritised investigation queue.

Full project management engine in Excel: CPM (Critical Path Method) with forward/backward pass, Earned Value Management metrics, automated resource levelling algorithm, dynamic Gantt chart driven by % Complete inputs, multi-department resource allocation heatmap, and VBA refresh engine with dependency cascade logic.

Complete supply chain intelligence system: EOQ with volume discount extension, Reorder Point with lead-time variability and service-level safety stock, seasonal demand decomposition (STL/Holt-Winters), ABC-XYZ inventory classification, Python ML demand forecasting pipeline, and Excel dynamic reorder dashboard with automated alert generation.

Contract intelligence pipeline: PDF text extraction with layout-aware parsing, 12-clause-class extraction (Liability, Indemnity, Termination, Governing Law, Limitation of Liability, IP Ownership, Confidentiality, Payment Terms, Dispute Resolution, Force Majeure, Auto-Renewal, Audit Rights), structured Excel master registry, and cross-vendor risk comparison matrix with deviation scoring.

Automated competitive intelligence system: structured raw data intake for competitor pricing and features, SWOT + Porter's Five Forces analysis engine, Competitive Positioning Matrix construction (Price vs. Value quadrant + feature gap heatmap), Python-generated analysis pipeline, Excel intelligence dashboard, and PowerPoint board-ready export with automated insight narration.

Builds a complete SaaS multi-currency financial modelling system in Excel: cohort-based MRR/ARR engine, churn waterfall with cohort survival curves, automated 3-scenario sensitivity stress-testing, PowerQuery M-code for live data refresh, and executive-grade dashboard with variance analysis cards.

Autonomous large-scale CSV data cleansing protocol: duplicate detection with fuzzy-match deduplication, 12-format date normalisation, categorical variable harmonisation, Z-score and IQR outlier flagging, Power BI schema compliance validation, and a full data quality audit report with per-field accuracy scoring.

Complete month-end close automation: master VBA or OfficeScript orchestrator that opens 5 source workbooks, extracts and cross-reconciles data, generates a consolidated P&L with variance analysis, applies error handling and audit logging, and auto-emails a formatted PDF to a stakeholder distribution list.

Full Modern Portfolio Theory implementation: covariance matrix construction, efficient frontier solver via SciPy optimisation, Sharpe ratio and Sortino ratio maximisation, Historical and Parametric VaR + CVaR at 95%/99% confidence, real-time price API integration via yfinance, and Excel Solver-based efficient frontier charting with asset weight sliders.

Builds a Strategic KPI Command Center in Excel: 5-pillar KPI architecture (Revenue, Marketing, Sales, Customer, Operations), automated Insight Generation cards that narrate the "why" behind metric movements, dynamic PowerQuery refresh, Excel-native conditional formatting signal lights, and a structured design system for CFO/CMO-ready presentation.

Board-grade Therapeutic Area assessment: 7-dimension scoring (UMN, market, competitive, regulatory, biology, IP, operational), Weighted Attractiveness Score (WAS), 3-branch strategic entry model (First-Mover/Fast-Follower/BD&L), rNPV ≥ 2.0× threshold enforcement, and mandatory bias audit.

C-suite market entry architecture across Pioneer / Disciplined Follow / Niche Beachhead scenarios: SAM/NSP modeling, gross-to-net discount, 5-year back-cast from Year 5 target, full HTA corridor mapping (NICE/G-BA/HAS/PMDA), and 5-barrier adversarial stress test.

Evidence-based corporate diversification evaluation: HHI portfolio concentration index, Ansoff Matrix + BCG Portfolio dual-framework, related/adjacent/unrelated branch tree, 3-round multi-agent CFO/CSO/Board debate, and ROIC vs. WACC value creation verdict.

Board-ready M&A investment memorandum: 7-dimension scientific diligence chain, bear/base/bull rNPV + synergy NPV, 6-scenario deal stress test (Phase III failure to competing bid), auction dynamics intelligence, mandatory PMI risk audit, and Bid/No-Bid/Conditional Bid recommendation.

McKinsey-caliber SWOT: 5 evidence-backed items per quadrant with competitive peer benchmarking, TOWS matrix generating 6 priority strategies with resource & KPI mapping, P&L financial translation ($M), and mandatory confirmation bias audit.

Board-grade risk register across 6 dimensions (clinical/regulatory/commercial/competitive/financial/operational): quantified Expected Loss and VaR at 95%, 3 adversarial scenario simulations (Phase III failure, competitive displacement, regulatory crisis), risk budget as % of EBITDA, and mandatory blind spot audit.

Executable 5-year pharma roadmap: back-cast from 6-dimension Year 5 vision, 4-phase gate milestones, 3 strategic trajectories (organic/M&A-driven/asset-light), 3-round CFO/CSO/Board debate mandate, rolling NPV + capex phasing bridge, and 5 competitive watchpoints with trigger protocols.

Territory-adjusted productivity audit: PRR (Productivity Realization Rate) per rep, 4-quadrant segmentation (High NRx+PRR through Low NRx+PRR), 4-source root cause framework (Territory/Tool/Management/Talent), revenue uplift quantification, adversarial OIG/ABPI compliance critique, and 30/60/90-day action plan.

Multi-objective territory design: workload modeling (TAST vs. TRCE Coverage Ratio), TPI potential equity scoring (PES), HHI relationship concentration risk, 5-scenario Pareto-optimal alignment (potential/workload/geography/continuity/balanced), disruption cost & break-even analysis, and adversarial vacancy stress test.

2×2 HCP priority matrix (potential × accessibility), DNC compliance gating, call frequency feasibility check (T1/T2/T3 vs. available selling days), pre-call/post-call quality architecture, omnichannel ABPI-compliant digital bridge design, and 3-round self-correction with manager coaching annotation.

40/40/20 commercial performance decomposition (market/strategy/execution), 3-level causal attribution cascade with % gap assignment, 5 leading indicator signals with NRx lag correlations, prior actions ACR accountability register, adversarial False Summit test, and Decision Log (Type A/B/C) capped at 5 priority actions.

OIG/ABPI-compliant IC plan design: Behavior-Metric-Outcome (BMO) framework, quota equity audit with demographic bias check, 4-scenario payout simulation (plan/outperform/underperform/formulary disruption), adversarial Anti-Kickback Statute compliance audit (42 U.S.C. § 1320a-7b(b)), and administration specification with claw-back protocol.

Propensity-based physician targeting: prescribing + behavioral + network + practice environment feature engineering, gradient boosting model with SHAP explainability, legacy decile lift analysis (NRx efficiency uplift $), tier assignment with plain-language rep cards, whitespace segment identification, and GDPR/HIPAA compliance audit with refresh protocol.

3-layer dashboard architecture: CCO 10-metric headline view (RAG with action triggers), BU Director operational drill-down, Regional Manager tactical territory view, 5-signal Early Warning Intelligence System (engagement decay/competitive reach/NTB stall/IC skew/BHPI deterioration), and weekly Narrative Engine generating 5-sentence commercial intelligence brief.

SCOR v12.0 + ISO 31000 risk intelligence: 7-step network topology mapping, 6-category risk taxonomy (supply/logistics/demand/regulatory/financial/force majeure), REI = P×I scoring matrix, 3-branch Critical Zone scenario analysis (30/60/>180 day disruption), Annualized Financial Exposure (AFE) calculation, and 7-item Meta-Evaluation Gate.

Full-spectrum dependency intelligence: HHI supply base concentration index, Supplier Dependency Score (SDS = spend × single-source × alternatives × switching cost), Kraljic Matrix segmentation (Strategic/Bottleneck/Leverage/Non-Critical), 3-branch dependency classification (volume/qualification/financial), hidden sub-tier convergence detection, and remediation roadmap for all SDS > 0.65.

Mathematically grounded inventory policy: ABC-XYZ 9-cell segmentation, EOQ = √(2DS/H) with full parameter derivation, safety stock SS = Z×√(LT×σd²+d̄²×σLT²) with 98-99% A-class targets, ROP = d̄×LT+SS, 3-scenario comparison (current/EOQ+SS/DDMRP), Bullwhip Ratio assessment, and working capital impact quantified in $ and days.

WHO TRS 961 + EU GDP 2013 + USP 1079 + IATA PCR simultaneous compliance assessment: product temperature classification, 7-node end-to-end route mapping (manufacture→patient), MKT calculation (ΔH/R formula), 3-branch excursion risk tree (monitored/undetected/systematic), regulatory gap register (Critical/Major/Minor), and CAPA roadmap with verification criteria.

24-month demand-driven capacity plan: OEE = Availability×Performance×Quality baseline per line, Takt Time vs. Cycle Time gap analysis, Theory of Constraints bottleneck identification by utilization rate, 3-scenario expansion modeling (OEE recovery/shift expansion/CMO outsourcing) with payback period, S&OP escalation trigger design, and revenue-at-risk quantification.

Dynamic geopolitical supply risk intelligence: PRI + World Bank Governance scoring per country, Tariff Exposure Index (TEI = spend% × tariff rate × policy instability), CAGE Distance Framework for nearshoring alternatives, 3-branch scenario modeling (tariff escalation/export control/sanctions embargo) for highest-exposure bilateral relationship, and network resilience strategy with force majeure contract upgrades.

ISO 22301-aligned activation-ready BCP: Business Impact Analysis with MTPD/RTO/RPO per critical function ($/day downtime rate), 3-scenario activation protocols (supplier failure/facility loss/cyber disruption) with Hour 1/Day 1/Week 1/Month 1 action sequences, pre-qualified recovery architecture, crisis communication tree with named alternates, and 6-item Meta-Evaluation Gate for activation readiness.

Multi-channel pharma campaign ROI decomposition: touchpoint attribution modeling (face-to-face/digital/medical education), incremental NRx per channel, MROI vs. benchmarks, budget reallocation scenarios, and ABPI/PhRMA-compliant interpretation — with explicit gross-to-net and managed care overlap adjustments.

Behavioral HCP segmentation beyond decile ranking: psychographic profiling (Innovator/Pragmatist/Traditionalist/Skeptic), evidence engagement pattern analysis, digital vs. F2F channel affinity scoring, segment-specific message architecture, and 30/60/90-day deployment roadmap with data refresh protocol.

Full brand positioning audit: 5-dimension competitive differentiation matrix (efficacy/safety/dosing/access/experience), claim substantiation strength scoring, payer vs. physician vs. patient message ladder, messaging hierarchy with MLR compliance flags, and repositioning scenario modeling with revenue impact estimates.

ABPI-compliant pharma digital marketing optimization: HCP portal engagement analytics, email sequence performance decomposition, paid search vs. organic vs. programmatic ROI, content resonance scoring by specialty, and a Q1–Q4 channel launch roadmap with budget allocation table and ROI forecast per channel.

Econometric marketing mix modeling: Adstock transformation with carryover decay estimation, diminishing returns curve per channel, media saturation threshold identification, price elasticity decomposition, share-of-voice vs. share-of-market regression, and budget reallocation with model uncertainty report.

Behavioral science-driven HCP patient journey mapping: 6-stage decision node analysis (awareness/consideration/trial/adoption/loyalty/advocacy), friction point identification with intervention priority matrix, moment-of-truth ranking by NRx conversion potential, and channel-specific message briefs for top 5 intervention windows.

Continuous brand health measurement system: 5-pillar KPI architecture (awareness/consideration/trial/loyalty/advocacy), early warning signal design with amber/red threshold triggers, competitive Brand Health Index (BHI) benchmarking, predictive NRx correlation (8–12 week lag), and brand health governance model with escalation protocols.

Tier-1 pharma market entry case: 7-dimension market attractiveness scoring, 3-pathway entry strategy (organic/partnership/acquisition), go-to-market model with launch sequencing, P&L construction with bear/base/bull scenarios, and McKinsey-style structured output with MECE issue tree and executive recommendation.

Therapeutic area expansion framework: portfolio adjacency mapping, capability fit scoring vs. target TA requirements, 3-horizon pipeline integration plan, competitive white space identification, make/buy/partner decision tree, and 10-year revenue bridge with TA entry investment threshold analysis.

Investment bank-grade biotech acquisition analysis: scientific diligence chain (MOA/PoS/regulatory precedent), bear/base/bull rNPV valuation, strategic fit scoring vs. acquirer LRP, synergy NPV decomposition, auction dynamics intelligence, and Bid/No-Bid/CVR structure recommendation with Board-ready investment thesis.

End-to-end commercial model transformation: SFE diagnostic across targeting/territory/IC/coaching dimensions, digital-physical channel integration blueprint, ROI attribution redesign, KPI architecture rebuild, change management sequencing, and 18-month transformation roadmap with milestone-based investment phasing.

Global pharma manufacturing network optimization: site-by-site COGS and OEE benchmarking, make/buy/outsource decision matrix per product family, footprint consolidation scenario modeling (3 options), regulatory risk assessment per site, capital investment vs. COGS reduction NPV, and 3-year implementation roadmap.

Multi-market pharmaceutical expansion framework: IRP (International Reference Pricing) cascade risk modeling, market prioritization matrix (attractiveness × access × speed), regulatory pathway comparison across 10+ markets, affiliate capability gap assessment, launch sequencing optimization, and IRP sensitivity analysis.

Big-3-grade CEO annual strategy review: 5-year portfolio stress test vs. competitive trajectory, growth gap decomposition (organic/BD/new platform), capital allocation rebalancing options, 3-scenario strategic planning model, Board-level narrative architecture (SCQA), and facilitation guide with pre-read and decision-forcing questions.

Multi-criteria pharma portfolio ranking: rNPV scoring with explicit PoS assumptions per development phase, strategic fit scoring (6 dimensions), resource constraint optimization across concurrent programs, kill/accelerate/partner decision logic, and weighted composite priority matrix with sensitivity analysis.

Zero-based R&D resource allocation: per-asset funding floor modeling (minimum viable Phase III investment), concurrent program capacity constraint analysis (max 3 parallel Phase III), opportunity cost calculation per reallocation scenario, and 1yr/3yr/5yr phased resource plan with LOE cliff and BD timeline integration.

Clinical stage-gate decision framework: clinical meaningfulness vs. statistical significance separation, out-licensing/pivot/discontinue alternative evaluation for No-Go decisions, TPP gap analysis, regulatory risk overlay, competitive timing pressure assessment, and structured recommendation with explicit assumption register.

Quantified portfolio risk register: financial impact ($M) per risk mandatory, correlated risk scenario modeling (Phase III failure cascade), clinical/regulatory/commercial/IP risk taxonomy, portfolio-level VaR calculation, risk concentration index (HHI across TA/modality/geography), and mitigation roadmap with residual exposure.

Composite pharma asset investment ranking: PoS × rNPV as primary signal (not market size alone), competitive differentiation scoring with named competitor benchmark, BD deal economics (upfront/milestone/royalty structure), peak sales bear/base/bull with penetration assumptions, and ranked investment priority table with go/watch/divest verdicts.

Strategic pipeline gap identification: TA coverage mapping vs. company strategy, LOE revenue cliff exposure by year, BD white-space prioritization with deal structure economics (upfront/milestone/royalty), modality capability gap assessment, and ranked in-licensing/acquisition target criteria with financial threshold modeling.

Full portfolio optimization: portfolio Expected Value (pEV) maximization across kill/accelerate/partner options, M&A appetite integration, organizational headcount constraint modeling, 3-horizon portfolio balance (launch/growth/early), risk-return efficient frontier construction, and 5-year portfolio transformation roadmap with Board-ready recommendation.

Dual-architecture (top-down + bottom-up) pharma sales forecast with gross-to-net waterfall, competitive share modelling, three-band scenario range, and a bias-corrected final estimate suitable for earnings guidance and S&OP submission.

Investor-grade launch forecast built on analogous launch data, back-cast coherence checks, three trajectory scenarios, launch-specific GTN modelling, and adversarial failure-mode stress testing for Year 1–5 revenue ramp.

Full commercial scenario planning framework: four-axis dimension tree, three fully specified scenarios with P&L sensitivity, finance vs. commercial multi-agent debate, trigger-event mapping, and anchoring bias audit.

Rigorous forecast accuracy review: MAPE/WMAPE/Bias decomposition, 5-Why root cause analysis, fishbone diagnostics, financial consequence quantification, and organisational bias audit with a formal improvement plan.

IBP-grade supply planning forecast: demand signal hierarchy, S&OP logic chain, safety stock calculation, three disruption scenario simulations (manufacturing hold, demand spike, API shortage), and adversarial failure-mode stress test.

Formal time-series decomposition for pharma demand: STL/X-13-ARIMA seasonal strength testing, five biological/channel seasonality mechanisms, quarterly revenue timing impact, and a spurious seasonality audit before any adjustment is applied.

Revenue-at-risk modelling for competitive entry: clinical and regulatory intelligence profiling, logistic erosion curve by entry type (new branded/biosimilar/generic), three-scenario revenue matrix, and adversarial defence strategy stress test.

HTA-submission-grade CEA: Markov/PSM/DES model selection, ICER calculation with DSA tornado and 10,000-run PSA, CEAC narrative, NICE/CADTH/PBAC jurisdiction-specific compliance, and adversarial ERG stress testing.

Payer-perspective BIM: epidemiology-driven patient flow, market uptake curve, per-patient cost breakdown, PMPM translation, 3×3 scenario matrix, displacement offset analysis, and payer-skeptic adversarial hardening.

Specialist QALY derivation: EQ-5D utility data hierarchy, health state utility assignment, AE disutility calculation, mapping algorithm specification with R² and MAE, and pre-rebuttal HTA challenge section for NICE/CADTH submissions.

Value-based pricing architecture: ICER back-calculation, analogue benchmarking, 15-market IRP corridor cascade, net price architecture, MEA typology selection, price sustainability modelling with biosimilar entry, and negotiator adversarial hardening.

8-domain traffic-light RRA: clinical efficacy, comparative safety, PRO/HRQoL, HEOR evidence, ITC/NMA, RWE, unmet need, and regulatory alignment — with evidence gap register, remediation plan, and accelerated access pathway check.

15-risk structured register across 6 categories: clinical evidence, HTA process, pricing & negotiation, policy & regulatory, competitive, and operational — with 2×2 priority matrix, 3-scenario value impact, and Go/No-Go recommendation.

5-tier payer intelligence map: national HTA body, HTA advisory experts, sub-national commissioners/PBMs, patient advocacy organisations, and KOL/DOL — with influence network, archetype messaging, ABPI/EFPIA-compliant engagement sequence.

7-phase commercial intelligence brief: data archaeology audit, 7-typology trend classification, 4-layer causal decomposition (market structure / access / promotional / competitive), leading vs. lagging signal separation, and 3-scenario Q+1/Q+2 forecast.

MPI-normalised territory analysis: Type A vs. Type B failure separation, 4-structural baseline metrics, 8-component performance decomposition, Q1–Q4 quadrant mapping, 6-factor Q2 root cause diagnostic, and execution + whitespace opportunity quantification.

Brand GM-ready intelligence brief: volume/revenue/lifecycle attainment, competitive threat matrix with covered lives impact, patient funnel forensics with revenue-at-risk quantification, and prescriber breadth vs. depth tension diagnosis.

4-gateway operationalisability-tested HCP segmentation: three parallel trees (behavioural / clinical-attitudinal / economic viability), cross-tree interaction effects, 4–6 composite archetype dossiers, and a field deployment matrix with investment allocation model.

Forensic commercial RCA: 6-dimension intake protocol, data artifact screen, triple causal tree investigation (demand / access-payer / competitive-promotional), evidence mapping with probability scoring, counterfactual stress test, and corrective action plan.

CFO-ready profitability intelligence: full GTN waterfall (mandatory/commercial/patient/distribution), gross margin to product contribution margin, patient lifetime value vs. CAC, LOE/biosimilar erosion modelling, and portfolio cannibalization analysis.

C-suite/Board EBR synthesis: 7-vital-sign dashboard, H1/H2/H3 strategic horizon intelligence, performance gap forensics, competitive intelligence brief, financial commitment review, go-to-market efficiency, uncomfortable truth protocol, and 3-decision executive agenda.

Multi-dimensional patient segmentation: ICD-10/CPT/NDC-anchored cohort construction, clinical + behavioral + socioeconomic feature engineering, proxy discrimination prohibition (no race/ethnicity as clustering feature), segment clinical profile × cost × care gap analysis, and care management program mapping with HIPAA-compliant output specification.

Epidemiological disease burden quantification: age-standardized prevalence/incidence mandatory, DALY decomposition (YLL + YLD), direct/indirect cost modeling (productivity loss, caregiver burden, payer spend), health equity stratification by SDoH variables, and AHRQ/HCUP/CMS benchmark comparison with population-level narrative for executive and payer audiences.

Clinical-grade adherence prediction: AUROC ≥ 0.72 enforcement gate, feature importance via SHAP explainability, non-adherence root cause taxonomy (economic/behavioral/clinical/system), 3-tier intervention protocol (low/medium/high-risk), prospective + retrospective validation framework, and deployment specification with regulatory context and explainability requirements.

Risk-adjusted hospital performance benchmarking: mandatory outcome risk-adjustment before any hospital comparison, CMS/Leapfrog/AHRQ peer group alignment, clinical quality × safety × operational efficiency × financial sustainability 4-domain framework, variation decomposition (patient mix vs. practice pattern vs. system factor), and executive brief with priority improvement roadmap.

HIPAA/HITECH-compliant Rx trend analysis: NRx/TRx/NBRx decomposition, prescriber segment trend attribution (new writer / growing / declining / lost), specialty drug class concentration analysis, formulary access and managed care event overlay, market share shift forensics, and YoY/Q-over-Q trend narrative with specialty drugs focus flag.

Prospective + retrospective population health risk stratification: composite risk score from clinical + claims + SDoH features, high/rising/stable/low-risk tier assignment, per-tier intervention program mapping with investment vs. avoidable cost ROI, population segmentation equity audit, and budget envelope allocation across care management programs.

HIPAA-secure healthcare analytics dashboard specification: rate-based KPI design (no raw counts as primary metrics), 3-tier user view architecture (executive/operational/clinical), EHR/claims/registry data source mapping, Tableau/Power BI/Cogito platform specification, alert threshold design with escalation logic, and HIPAA environment classification (secure EHR / analytics sandbox / public-facing).

OODA-driven pipeline intelligence: 4-axis asset assessment (clinical differentiation/speed/commercial potential/IP durability), full patent estate mapping (composition/method of use/formulation/data exclusivity), PTRS estimates with source citation (BioMedTracker/Citeline), MOA convergence mapping with crowded pathway risk flag, and probability-weighted threat matrix with time-to-market intervals.

Strategic clinical trial surveillance: ClinicalTrials.gov/EMA EPAR/PMDA multi-registry monitoring, enrollment velocity signal extraction, protocol amendment change log interpretation, data readout timeline projection with confidence intervals, 18-month conference calendar (ASCO/ESMO/ASH/ADA/AHA) mapping, and Level 3+ signal immediate action recommendations.

Evidence-grounded competitive scorecard: 5-dimension benchmarking matrix (clinical/commercial/operational/financial/innovation), primary source validation mandatory (no unanchored scores), 24-month competitive trajectory modeling, capability whitespace identification, defensive position strength assessment, and 3 strategic recommendations to defend or expand competitive position.

BD partnership landscape intelligence: deal flow mapping by competitor × modality × therapeutic area, financial terms benchmarking (upfront/milestones/royalties from SEC EDGAR), strategic intent classification (capability acquisition/geographic expansion/pipeline fill/platform licensing), reverse intelligence vulnerability assessment, and 3 BD opportunity recommendations.

M&A signal triangulation: acquirer appetite scoring from pipeline gaps + cash position + leadership signals, target attractiveness matrix (pipeline stage/IP durability/strategic fit), comparable transaction analysis with rNPV range for top 3 targets, deal structure prediction (full acquisition/option/collaboration), and 3-scenario competitive impact assessment.

Competitor launch readiness surveillance: commercial infrastructure signal tracking (hiring velocity/speaker bureau/digital footprint), payer negotiation intelligence (formulary submission indicators/HEOR publication cadence), medical education program mapping, reimbursement readiness gap analysis, launch timeline triangulation, and 90-day action plan for commercial and market access teams.

Board-distribution-ready quarterly CI report: three-question executive framework (What changed / What it means / What we do), signal-to-noise filtered intelligence (primary source only), competitive event log with impact severity scoring, portfolio decision impact assessment, forward-looking intelligence calendar, and strategic recommendations with owner/timeline/escalation path.

Tiered influence scoring with 7-criterion KIS model, Social Network Analysis (degree/betweenness/closeness/eigenvector centrality), competitive alignment heat map, MSL engagement ROI framework, and a 5-bias influence inflation audit. Identifies top hub/bridge KOLs and competitor-aligned acquisition targets.

6-category stakeholder ecosystem decomposition (clinical/payer/patient/regulatory/economic/external), Mendelow Power-Interest placement, influence pathway chain-of-thought for top 5 actors, conflict simulation with resolution, Stakeholder Influence Value (SIV) financial quantification, and omission + echo chamber bias audit.

Dual-architecture market sizing: 7-step epidemiology cascade (top-down) + decile-based prescriber model (bottom-up), back-cast from peak potential, GTN-adjusted TAM/SAM/SOM with 3-scenario range, IRA exposure modeling, and a 4-bias market optimism audit covering diagnosis inflation, eligibility overcount, market share fantasy, and price stability illusion.

Tripartite VoC architecture (HCP/Patient/Payer), Adaptive Choice-Based Conjoint for HCP attribute weighting, MaxDiff outcome prioritization for patients, payer advisory board with mock HTA submission exercise, NPS brand tracking, insight-to-revenue translation for each key finding, and a 4-bias audit (social desirability, framing, anchoring, novelty effect).

Triple-axis HCP segmentation (IQVIA volume decile + behavioral prescribing pattern + Rogers adoption curve attitudinal), k-means/latent class clustering with elbow + silhouette + discriminant validation, Segment Opportunity Index, field force ROI by segment, competitive white space mapping, and a 3-failure-mode actionability audit (stability, actionability, over-granularity).

6-domain TA intelligence landscape (biology/epidemiology/treatment algorithm/pipeline/access-policy/commercial investment), competitive intensity scoring with vulnerability mapping, 3-branch TA evolution analysis (incremental/platform disruption/indication expansion wave), TA Investment Score (TAIS 0–100), required return calculation, and a 5-question hype vs. scientific reality audit.

5-dimension unmet need framework, competitive gap mapping (ClinicalTrials.gov/FDA/patent verification), entry pathway analysis with rNPV and cost per mode (own dev/licensing/acquisition), Optimist vs. Skeptic multi-agent debate with Arbiter verdict, back-cast entry timeline to market, and 5-test White Space vs. Brick Wall audit (Graveyard, Invisibility, Regulatory Path, Willingness-to-Pay, Capability).